Novo Nordisk and Eli Lilly Penalized by French Regulator for Weight Loss Advertising

France's medicines regulator has issued fines to both Novo Nordisk and Eli Lilly concerning their advertising strategies for weight loss products.

The fines highlight regulatory concerns over the marketing practices employed by these companies in promoting their weight loss campaigns.

This action reflects ongoing scrutiny in the pharmaceutical industry regarding advertising ethics and the promotion of weight loss treatments.